Cardiac function disturbance postoperative – European Clinical Trials Information Network

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Wed, 29 Apr 2026 15:09:16 +0000

This study focuses on preventing Acute Kidney Injury, which is a sudden episode of kidney failure or damage that happens or develops within a short period of time. The research is specifically looking at patients at high risk for this condition following Cardiac Surgery, such as procedures involving the heart valves, the aorta, or a Coronary Artery Bypass Graft. These surgeries often require the use of a Cardiopulmonary Bypass machine, which is a device that temporarily takes over the function of the heart and lungs during the operation.

The purpose of the study is to evaluate the safety and effectiveness of a drug called R2R01. This medication is a Relaxin Agonist, which is a type of substance designed to activate specific proteins in the body to achieve a therapeutic effect. During the study, participants will receive either R2R01 or a placebo containing Sodium Chloride via a subcutaneous injection, which is an injection given into the fatty tissue just under the skin.

Participants will be assigned to different groups to receive different doses of the medication or the placebo. The study is double-blind, meaning that neither the participants nor the medical staff know which substance is being administered. The course of the study involves monitoring the participants after their surgery to observe how their kidneys function and to track any side effects that may occur.

Study on Preventing Acute Kidney Injury After Heart Surgery Using Empagliflozin in Patients Undergoing Elective Cardiac Surgery

Wed, 29 Apr 2026 15:03:38 +0000

This clinical trial is focused on studying a condition known as cardiac surgery-associated acute kidney injury. This condition can occur in patients who undergo heart surgery and involves damage to the kidneys. The study will explore the effects of a medication called empagliflozin, which is taken as a film-coated tablet. Empagliflozin is a type of drug known as a sodium-glucose cotransporter 2 inhibitor, which is typically used to help control blood sugar levels in people with diabetes.

The purpose of this study is to determine if taking empagliflozin once daily around the time of surgery can reduce the chances of developing acute kidney injury in patients who are having planned heart surgery that involves the use of a heart-lung machine. Some participants in the study will receive empagliflozin, while others will receive a placebo, which looks like the medication but does not contain the active ingredient. This helps researchers understand the true effect of the medication.

Participants in the study will take the medication or placebo for a period of time before and after their surgery. The study will monitor the participants’ kidney function and overall health for up to 90 days following their surgery to see if there is any improvement or change in their condition. The goal is to find out if empagliflozin can help protect the kidneys during and after heart surgery.

Study on Reducing Acute Kidney Injury After Heart Surgery Using Angiotensin II or Noradrenaline for Patients with Low Blood Pressure

Wed, 29 Apr 2026 15:03:12 +0000

This clinical trial is focused on managing Acute Kidney Injury (AKI), a condition where the kidneys suddenly stop working properly, often after heart surgery. The study will compare two treatments: Angiotensin II, a medication that helps regulate blood pressure, and Noradrenaline (also known as norepinephrine), which is commonly used to increase blood pressure in patients with low blood pressure. The purpose of the study is to see if using Angiotensin II can reduce the occurrence of moderate or severe AKI within 72 hours after cardiac surgery.

Participants in the study will receive either Angiotensin II or Noradrenaline through an intravenous infusion, which means the medication will be delivered directly into the bloodstream. The study will last for a maximum of three days, during which the effects of the treatments on kidney function will be closely monitored. The goal is to determine which treatment is more effective in preventing AKI after heart surgery.

The study will also look at other outcomes, such as the rate of death or the need for dialysis within 90 days, and any long-term changes in kidney function. By comparing these two treatments, researchers hope to find a better way to manage blood pressure and protect kidney function in patients undergoing heart surgery.

Study on Alkaline Phosphatase to Prevent Inflammation and Kidney Injury in Patients Undergoing Open-Heart Surgery

Wed, 29 Apr 2026 15:03:04 +0000

This clinical trial is focused on patients undergoing open-heart surgery, specifically those who experience systemic inflammation as a side effect of using a heart-lung machine during the procedure. The study is investigating a treatment called RESCAP iv, which contains an active substance known as alkaline phosphatase, bovine. This treatment is given as a solution for injection or infusion. The purpose of the study is to see if RESCAP iv can help reduce complications that occur during and after heart surgery.

Participants in the study will receive either the RESCAP iv treatment or a placebo, which looks the same but does not contain the active substance. The study will monitor how quickly patients reach stability in the intensive care unit (ICU) and whether the treatment can reduce the occurrence and severity of acute kidney injury after surgery. Acute kidney injury is a condition where the kidneys suddenly stop working properly, and it can be measured by changes in blood tests and urine output.

The study will follow patients for up to 90 days after their surgery to assess the effects of the treatment. The goal is to determine if RESCAP iv can improve recovery and reduce the risk of complications associated with heart surgery. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effectiveness.

Study on Fibrinogen Concentrate (FGTW) for Managing Bleeding in Patients Undergoing Complex Cardiac Surgery

Wed, 29 Apr 2026 14:29:31 +0000

This clinical trial is focused on managing bleeding in patients who are undergoing complex heart surgery, specifically those involving a procedure called cardiopulmonary bypass (CPB). The study is investigating the use of a treatment called fibrinogen concentrate, which is also known by its code name FGTW. Fibrinogen is a protein that helps blood to clot, and the concentrate is being tested to see if it can reduce the need for blood transfusions during and after surgery. The trial will compare the effects of FGTW with a placebo to determine its effectiveness and safety.

The purpose of the study is to evaluate whether FGTW, when used alongside standard care, can decrease the need for transfusions of blood products within the first 24 hours after surgery. Participants in the study will receive either the fibrinogen concentrate or a placebo through an intravenous infusion, which means the treatment is delivered directly into the bloodstream. The study will monitor the amount of blood products needed, the volume of blood drainage, and other health outcomes over a period of time, including the length of hospital stay and any complications that may arise.

By participating in this study, researchers aim to gather important information on how effective FGTW is in managing bleeding during complex heart surgeries. This could potentially lead to improved treatment options for patients undergoing such procedures. The study is expected to continue until 2026, with recruitment having started in October 2023.